Abstract: To investigate this in vitro, we generated novel stable cell lines expressing HBV encoding the four major patterns of lamivudine resistance mutations (rtL180M+rtM204V, rtV173L+rtL180M+rtM204V, rtM204I and rtL180M+ rtM204I).
Clinical reactivation during lamivudine treatment correlates with mutations in the precore/core promoter and polymerase regions of hepatitis B virus in patients with anti-hepatitis B e-positive chronic hepatitis.
Abstract: RESULTS: 'Polymerase region': M204V/I variants were found in all group A patients, but in none of group B1 (P=0.0007) and in four of nine of group B2 (44%; P=0.02) patients.
Hepatitis B virus DNA quantitation and detection of core promoter, precore and polymerase mutations in chronic hepatitis B: evaluation and clinical usefulness of three new commercial assays.
Abstract: affigene HBV mutant VL (positions G1764A, G1896A) and affigene HBV DE/3TC (positions rtL180M, rtM204V/I) were able to detect a low presence of mutants in a mixed population (wild type and mutant) compared to direct sequencing and Inno-LIPA HBV DR, which identified only the dominant population.
Abstract: Add-on adefovir therapy is effective in suppressing rtM204 I/V in both compensated and decompensated patients.
Abstract: However, HBV species with mutations in the tyrosine-methionine-aspartate-aspartate (YMDD) locus of the HBV RNA-dependent DNA polymerase (rtM204 I/V) conferring resistance to lamivudine may emerge after 9-10 months therapy.
Abstract: Serum alanine aminotransferase (ALT) elevation and HBV DNA rebound ( I log) occur in >90% of the patients with rtM204 I/V during continued lamivudine therapy.
Abstract: The initial clinical and histologic improvement may also reverse after emergence of rt
Detection of hepatitis B virus variants resistant to lamivudine and famciclovir among randomly selected chronic carriers from Spain.
PMID: 14987532
2004
Enfermedades infecciosas y microbiologia clinica
Abstract: Wild-type strains together with either the rtM204I (M552I) or rtV207I (V555I) point mutation were found in two of these cases, and the rtV207I mutation alone was detected in the third.
No benefit to continue lamivudine therapy after emergence of YMDD mutations.
Abstract: AIM: To evaluate whether continuing lamivudine therapy after emergence of rt M 204 I/V is appropriate.
Abstract: BACKGROUND: Mutations in the sequence of the conserved tyrosine-methionine-aspartate-aspartate (YMDD) locus of the HBV RNA-dependent DNA polymerase (rt M 204 I/V) may develop after 6-9 months of lamivudine therapy.
Abstract: CONCLUSION: These results suggest that there is no benefit to continued lamivudine therapy after emergence of rt M 204 I/V.
Abstract: In addition, experiments have shown that the defective replication competency of rt PMID: 15261293
2004
Bioorganic & medicinal chemistry letters
Abstract: Molecular modeling studies of adefovir diphosphate with the wild type and the mutant HBV polymerase-DNA complex demonstrated that the increase in adefovir sensitivity toward HBV polymerase mutants (rtL180M, rtM204V/I, rtL180M-M204V/I) is a result of increased van der Waals interaction and is supplemented by the decreased affinity of natural substrate toward the mutant HBV polymerase.
Basal core promoter and precore mutations in the hepatitis B virus genome enhance replication efficacy of Lamivudine-resistant mutants.
Abstract: Resistance to LMV (rtM204I/rtL180M+rtM204V) was accompanied by a reduced replication efficacy as evidenced by reduced pregenomic RNA, encapsidated progeny DNA, polymerase activity, and virion release.
Abstract: Treatment of chronic HBV infection with lamivudine (LMV) often selects drug-resistant strains with single (rtM204I) or double (rtL180M+rtM204V) point mutations in the YMDD motif of HBV reverse transcr
Pyrosequencing for detection of lamivudine-resistant hepatitis B virus.
PMID: 15472342
2004
Journal of clinical microbiology
Abstract: Lamivudine-resistant HBV mutants display specific mutations in the YMDD (tyrosine, methionine, aspartate, aspartate) motif of the viral polymerase (reverse transcriptase [rt]), which is the catalytic site of the enzyme, i.e., methionine 204 to isoleucine (rtM204I) or valine (rtM204V).
HBV mutation literature information.
PMID: 
2005
Journal of viral hepatitis
Browser Board
Co-occurred Entities
Filtrator
ViMRT